Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 7/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.45 |
| ▸ | BCR | P11274 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 5/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.42 |
| ▸ | KIF5B | P33176 | 1/20 | 0.42 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ABL2 | P42684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15696777 | 0.96 | KIT (0.48) | ABL1KITRETKIF5BCCDC6 | |
| SCHEMBL17182026 | 0.93 | MKNK2 (0.50) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL17182124 | 0.91 | KIT (0.46) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL17181836 | 0.88 | ABL1 (0.45) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL15687882 | 0.87 | KIT (0.45) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL17181912 | 0.87 | KIT (0.51) | ABL1BCRKITRETKIF5B | |
| SCHEMBL17182037 | 0.87 | MKNK2 (0.42) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL17182093 | 0.86 | KIT (0.41) | ABL1MKNK2MKNK1BCRKIT | |
| SCHEMBL17182098 | 0.86 | KIT (0.45) | ABL1BCRKITRETKIF5B | |
| SCHEMBL15687926 | 0.86 | KIT (0.45) | ABL1MKNK2MKNK1BCRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2917214-B1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-28 | — | — | EP | disclosed |
| US-9604980-B2 | Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-28 | — | — | US | disclosed |
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299192-A1 | SUBSTITUTED PYRIMIDINYL AND PYRIDINYL-PYRROLOPYRIDINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | RET, MAP3K8, MAP3K1 | ABL1 35/4885MKNK2 48/4885MKNK1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.